文献速递泌尿生殖与妇科肿瘤放疗

高危前列腺癌的立体定向消融放疗:两项前瞻性临床试验伴或不伴选择性淋巴结照射的结果

SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-11-14

本研究比较了两项在高危前列腺癌中应用立体定向消融放疗(SABR)的前瞻性2期试验,一项伴选择性淋巴结照射(ENI),一项不伴。结果显示,ENI组生化失败率为0%,无ENI组为14.6%(5年),且ENI未增加晚期胃肠或泌尿生殖毒性。作者认为ENI可行,可能改善生化控制,但需更长期随访和3期试验确认。

要点

  • 高危前列腺癌SABR的5年生化失败率:无ENI组14.6%,ENI组0%。
  • ENI组4年PSA应答率93%,无ENI组63%。
  • 无ENI组晚期胃肠和性毒性显著更差,晚期泌尿生殖毒性无差异。

核心结论

  • 高危前列腺癌SABR的生化控制率可能与其他放疗模式相当。
  • SABR联合ENI可行,可能显著改善生化控制和4年PSA应答率,且不增加晚期胃肠或泌尿生殖毒性。
  • 更长期随访有助于更好地评估生化控制。
  • 需要精心设计的3期试验来完全确定SABR和ENI在高危前列腺癌中的作用。

研究设计与样本

  • 比较两项前瞻性2期试验,共纳入60例高危前列腺癌患者(试验1 n=30,试验2 n=30)。
  • 试验1:前列腺40 Gy分5次,精囊腺30 Gy分5次。
  • 试验2:前列腺40 Gy分5次,盆腔和精囊腺25 Gy分5次。
  • 采用美国国家癌症研究所常见不良事件术语标准收集毒性。
  • 生化失败定义为nadir+2,4年PSA应答率定义为<0.4 ng/mL。

主要发现

  • 中位随访时间:试验1为5.6年,试验2为4.0年。
  • 两试验的中位PSA最低值均为0.02 ng/mL。
  • 6例患者出现生化失败,全部来自试验1;试验1的5年生化失败率为14.6%,试验2为0%。
  • 试验1的4年PSA应答率为63%,试验2为93%。
  • 试验1中2例死亡(1例死于转移性疾病),试验2中1例死于其他原因;无其他患者发生转移,试验1中1例出现去势抵抗性前列腺癌。

关键数值与推荐

  • 生化失败定义:nadir+2。
  • 4年PSA应答率定义:PSA <0.4 ng/mL。
  • 试验1放疗剂量:前列腺40 Gy/5次,精囊腺30 Gy/5次。
  • 试验2放疗剂量:前列腺40 Gy/5次,盆腔和精囊腺25 Gy/5次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 随访时间较长但仍有待延长,原文指出更长期随访有助于更好地评估生化控制。
  • 原文指出需要精心设计的3期试验来完全确定SABR和ENI在高危前列腺癌中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is limited data on stereotactic ablative radiation therapy (SABR) in high-risk prostate cancer (PCa), especially regarding the role of elective nodal irradiation (ENI). This study compares 2 prospective phase 2 trials using SABR in high-risk PCa, with and without ENI. METHODS AND MATERIALS: Patients had high-risk PCa. Those in trial 1 received 40 Gy in 5 fractions to the prostate and 30 Gy in 5 fractions to the seminal vesicles. Patients in trial 2 received 40 Gy in 5 fractions to the prostate and 25 Gy in 5 fractions to the pelvis and seminal vesicles. National Cancer Institute Common Terminology Criteria for Adverse Events toxicities were collected. Biochemical failure (BF) was defined as nadir + 2, and the 4-year prostate-specific antigen (PSA) response rate (4yPSARR) was <0.4 ng/mL. RESULTS: Sixty patients were included (trial 1, n = 30; trial 2, n = 30). Median follow-up was 5.6 years and 4.0 years. The median nadir PSA was 0.02 ng/mL for both trials. Six patients had BF, all from trial 1. The BF rate was 14.6% at 5 years in trial 1 and 0% in trial 2. Sixty-three percent of patients in trial 1 and 93% in trial 2 had a 4yPSARR. Two patients died in trial 1, 1 from metastatic disease. One patient in trial 2 died of other causes. No other patients developed metastatic disease, and 1 patient in trial 1 had castrate resistant PCa. Overall survival at 5 years was 93.2% and 96.7% (P = .86). There was significantly worse late gastrointestinal and sexual toxicity in trial 1, but there was no difference in late genitourinary toxicity. CONCLUSIONS: SABR in high-risk PCa yields biochemical control rates that may be comparable to that of other radiation therapy modalities. ENI using SABR is feasible and may lead to a significant improvement in biochemical control and in 4yPSARR, without an increase in late gastrointestinal or genitourinary toxicity. Longer follow-up would provide a better assessment of biochemical control. Well-conducted phase 3 trials are needed to fully establish the role of SABR and ENI in high-risk PCa.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Alayed Y, Cheung P, Vesprini D, et al. SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation. Int J Radiat Oncol Biol Phys. 2018. PMID: 30445172. doi:10.1016/j.ijrobp.2018.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。